Table 2.

Predictors of subjective quality of sleep and nocturnal akinesia

	β	SE	t value	p value
Predictors of quality of sleep (PDSS-2 sum score)
Disease duration	− 0.29	0.19	− 1.55	0.13
MDS-UPDRS III	0.01	0.06	0.13	0.90
MDS-UPDRS IV	0.95	0.25	3.74	< 0.001
Levodopa daily dosage (mg)	0.01	0.00	2.65	0.009
Levodopa CR daily dosage (mg)	0.02	0.00	2.95	0.004
R2	0.35
Corrected R2	0.31

	β	SE	t value	p value
Predictors of nocturnal akinesia (PDSS-2 question 9)
Disease duration	− 0.29	0.19	− 1.55	0.13
MDS-UPDRS III	0.01	0.06	0.13	0.90
MDS-UPDRS IV	0.95	0.25	3.74	< 0.001
Levodopa daily dosage (mg)	0.01	0.00	2.65	0.009
Levodopa CR daily dosage (mg)	0.02	0.00	2.95	0.004
R2	0.34
Corrected R2	0.30

β non-standardized β-regression coefficient, SE standard error of β-regression coefficient; MDS-UPDRS Movement Disorder Society Unified Parkinson’s Disease Rating Scale p level of significance